10x Genomics $TXG Shares Sold by Inscription Capital LLC

Inscription Capital LLC lessened its position in shares of 10x Genomics (NASDAQ:TXG) by 65.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 18,323 shares of the company’s stock after selling 33,999 shares during the quarter. Inscription Capital LLC’s holdings in 10x Genomics were worth $1,656,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TXG. Quantinno Capital Management LP raised its holdings in shares of 10x Genomics by 16.0% during the 1st quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock worth $114,892,000 after acquiring an additional 744,558 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in 10x Genomics by 34.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock valued at $43,357,000 after purchasing an additional 525,369 shares in the last quarter. Quantedge Capital Pte Ltd grew its stake in shares of 10x Genomics by 104.2% in the 1st quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock worth $8,843,000 after buying an additional 212,600 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of 10x Genomics during the 1st quarter valued at about $5,945,000. Finally, Swiss National Bank grew its position in 10x Genomics by 2.2% in the first quarter. Swiss National Bank now owns 207,400 shares of the company’s stock worth $4,403,000 after acquiring an additional 4,400 shares in the last quarter. Institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Argus assumed coverage on 10x Genomics in a research note on Monday, September 28th. They set a “buy” rating and a $110.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a research note on Monday, September 21st. Citigroup boosted their target price on 10x Genomics from $45.00 to $50.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Stifel Nicolaus set a $70.00 price objective on shares of 10x Genomics in a research report on Tuesday, October 13th. Finally, Canaccord Genuity Group upped their price target on shares of 10x Genomics from $60.00 to $100.00 and gave the company a “buy” rating in a report on Monday, October 12th. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and a consensus target price of $68.00.

10x Genomics Trading Down 14.0%

NASDAQ:TXG opened at $58.06 on Friday. The stock has a fifty day simple moving average of $74.06 and a 200-day simple moving average of $41.41. The company has a market cap of $7.56 billion, a price-to-earnings ratio of -98.41 and a beta of 2.03. 10x Genomics has a twelve month low of $12.80 and a twelve month high of $102.81.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.12. The company had revenue of $150.67 million for the quarter, compared to the consensus estimate of $147.96 million. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The firm’s revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.22) EPS. As a group, equities research analysts predict that 10x Genomics will post -0.77 EPS for the current fiscal year.

Insider Activity

In other 10x Genomics news, CFO Adam Taich sold 46,388 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total transaction of $2,995,273.16. Following the transaction, the chief financial officer directly owned 316,344 shares in the company, valued at $20,426,332.08. This trade represents a 12.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 13,818 shares of 10x Genomics stock in a transaction on Monday, August 24th. The shares were sold at an average price of $63.02, for a total value of $870,810.36. Following the sale, the insider directly owned 488,182 shares of the company’s stock, valued at approximately $30,765,229.64. This trade represents a 2.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 179,333 shares of company stock valued at $11,810,070. Insiders own 8.84% of the company’s stock.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q3 revenue was $150.7 million, above the roughly $148 million consensus, while the loss of $0.15 per share was narrower than analysts’ expected loss of $0.27. Revenue increased 1.1% year over year. Article: 10x Genomics Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: The company forecast 2026 revenue of $625 million to $635 million and said it is targeting about 50 Atera shipments by year-end, providing a revenue outlook and a near-term product milestone. Article: 10x Genomics Forecasts 2026 Revenue and Atera Shipments
• Neutral Sentiment: Broader technology stocks were volatile, with a report noting a sharp Nasdaq decline followed by a bounce. That market backdrop may have added uncertainty, but the article does not identify a TXG-specific effect. Article: Dow Jones Futures Fall, Techs Bounce
• Negative Sentiment: Despite the earnings beats, TXG declined after the results. The quarter still showed only 1.1% year-over-year revenue growth and a net loss, which may have tempered investor enthusiasm. Article: Q3 Sales Top Estimates but Stock Drops

About 10x Genomics

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.